Insulet Unveils EVOLUTION 2 Data on Type 2 Diabetes Closed-Loop System at ATTD
Event summary
- Insulet will present EVOLUTION 2 study results on its Omnipod® Fully Closed-Loop System for Type 2 Diabetes at ATTD on March 11, 2026.
- The symposium, chaired by Dr. Trang Ly, will feature presentations on glycemic improvements and market expansion.
- Seven additional posters and presentations on Omnipod 5 and future innovations will be showcased during the conference.
- Insulet will host exhibit hall activities, including product demonstrations and podcast recordings.
- A webcast featuring Dr. Ly and Jeff Johnson of Baird will recap ATTD highlights on March 13, 2026.
The big picture
Insulet's presentation of EVOLUTION 2 data marks a significant step in expanding its Omnipod® technology into the Type 2 Diabetes market, a segment with substantial unmet needs. The company's focus on simplifying diabetes management aligns with broader industry trends toward automated insulin delivery systems. Success in this area could position Insulet as a leader in tubeless insulin pump technology, potentially driving revenue growth and market share.
What we're watching
- Clinical Efficacy
- How the EVOLUTION 2 study results will impact the adoption of Omnipod® Fully Closed-Loop System among Type 2 Diabetes patients.
- Market Expansion
- Whether Insulet can sustain its market expansion efforts and future product innovations.
- Competitive Positioning
- The pace at which Insulet can differentiate itself in the automated insulin delivery market.
Related topics